Literature DB >> 11569683

Long term survival after pancreatic resection for pancreatic adenocarcinoma.

N A Ahmad1, J D Lewis, G G Ginsberg, D G Haller, J B Morris, N N Williams, E F Rosato, M L Kochman.   

Abstract

OBJECTIVE: The aim of this study was to determine the long term survival of patients with pancreatic adenocarcinoma who underwent surgical resection and to assess the association of clinical, pathological, and treatment features with survival.
METHODS: Between January, 1990, and December, 1998, 125 patients underwent a pancreaticoduodenal or partial pancreatic resection for pancreatic ductal adenocarcinoma at our institution. The records of these patients were reviewed for demographics, tumor characteristics including size, histological grade, margin status, lymph node status, surgical TNM staging, and postoperative adjuvant therapy. The primary outcome variable analyzed was survival.
RESULTS: A total of 116 patients had complete follow-up and were included in the final analysis. The median survival after surgery was 16 months. The 1-, 3-, 5-, and 7-yr survival rates for all 116 patients were 60%, 23%, 19%, and 11%, respectively. The 1-, 3-, 5-, and 7-yr survival rates for patients who received adjuvant therapy were 69%, 28%, 23%, and 18% compared with 20% and 0% in patients who did not receive adjuvant therapy (p < 0.0001). The 1-, 3-, 5-, and 7-yr survival rates for patients with negative lymph nodes were 73%, 38%, 26%, and 22% compared with survival rates of 52%, 14%, 14%, and 9% in patients with positive lymph nodes (p = 0.01). In multivariate analyses, adjuvant therapy was the only feature found to be strongly associated with survival (hazards ratio = 0.26, 95% CI = 0.15-0.44).
CONCLUSIONS: The overall 5- and 7-yr survival rates of 19% and 11% in our study further validate that surgical resection in patients with pancreatic adenocarcinoma can result in long term survival, particularly when performed in association with adjuvant chemoradiation.

Entities:  

Mesh:

Year:  2001        PMID: 11569683     DOI: 10.1111/j.1572-0241.2001.04123.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  37 in total

1.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

2.  Extraintestinal Applications of Endoscopic Ultrasound.

Authors:  Rayburn Rego
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-04

3.  Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Janusz Strzelczyk; Adam Janiak; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

4.  Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.

Authors:  Alireza Aslani; Anthony J Gill; Paul J Roach; Barry J Allen; Ross C Smith
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 5.  A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma.

Authors:  James R Butler; Syed A Ahmad; Matthew H Katz; Jessica L Cioffi; Nicholas J Zyromski
Journal:  HPB (Oxford)       Date:  2016-02-01       Impact factor: 3.647

Review 6.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 7.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

8.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

9.  Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas.

Authors:  Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  HPB (Oxford)       Date:  2013-03-08       Impact factor: 3.647

10.  Rare long-term survivors of pancreatic adenocarcinoma without curative resection.

Authors:  Stephen Y Oh; Alicia Edwards; Margaret T Mandelson; Bruce Lin; Russell Dorer; W Scott Helton; Richard A Kozarek; Vincent J Picozzi
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.